Biotech Archives - Page 677 of 795

2 minute read

Enanta Pharmaceuticals Initiates A Phase 2b Clinical Study Of EDP-938 In High-Risk Adults With Respiratory Syncytial Virus

October 3, 7:09 AM

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the initiation of a Phase 2b,

ENTA

1 minute read

Clovis Oncology Announces TRITON3 Phase 3 Trial Of Rubraca Achieves Primary Endpoint In Men With Metastatic Castration-Resistant Prostate Cancer With BRCA Or ATM Mutations

By Benzinga Newsdesk

October 3, 7:07 AM

TRITON3 study evaluating Rubraca monotherapy versus chemotherapy or second-line androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations in BRCA or ATM

CLVS

1 minute read

Theseus Pharmaceuticals Nominates THE-349, A Fourth-Generation EGFR Inhibitor Development Candidate In Non-Small Cell Lung Cancer

By Benzinga Newsdesk

October 3, 7:04 AM

THE-349 is a fourth-generation, potent and selective, small molecule designed to inhibit all major classes of EGFR activating and resistance mutations Preclinical data to be presented at the 34th EORTC-NCI-AACR

THRX

2 minute read

BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data At HFSA Annual Meeting

By Benzinga Newsdesk

October 3, 7:01 AM

BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces data from its FDA designated Breakthrough

BCDA

1 minute read

SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ AAC Platform’s Potential As An Effective Red Blood Cell-Derived Immunotherapy

By Benzinga Newsdesk

October 3, 6:46 AM

Activating Antigen Carriers (AACs) Shown Preclinically to Activate CD8 T Cells, Increase Their Tumor Infiltration and Drive Tumor Killing Demonstrated Improved Efficacy of AAC Therapy Through Combination with

SQZ

4 minute read

AstraZeneca-Merck’s Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October’s Key PDUFA Catalysts Biotech Investors Must Know

By Shanthi Rexaline

October 2, 9:49 AM

Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the total NME approvals for the year to 24. This is far less than the 40 approvals received by the same time last year.

ALNY

5 minute read

Alnylam Presents Additional Results From The APOLLO-B Phase 3 Study Of Patisiran In Patients With ATTR Amyloidosis With Cardiomyopathy At Heart Failure Society Of America Annual Meeting

By Benzinga Newsdesk

September 30, 2:03 PM

– New Data Further Support Potential for Patisiran to be an Effective Treatment for Cardiomyopathy of ATTR Amyloidosis – – Data from Exploratory Endpoints, Including Cardiac Biomarkers and Imaging,

ALNY

1 minute read

FDA Says Livanova Recalls Lifesparc System For Risk Of Unintentional Extended Pump Stop During Controller Critical Failure

By Benzinga Newsdesk

September 30, 10:49 AM

- Reuters

LIVN

1 minute read

Aileron Therapeutics Announces Oral Presentation Of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles And Their Stem Cells From Chemotherapy-Induced Damage At The European Society For Dermatological Research Annual Meeting 2022

By Benzinga Newsdesk

September 30, 8:43 AM

New ex vivo data demonstrates protection against cyclophosphamide-induced damage to hair follicles and their stem cells Encore presentation of data presented at Society for Investigative Dermatology in May

ALRN

2 minute read

Edesa Biotech Reports Statistically Significant Mortality Reductions In Phase 2 ARDS Drug Study; Says ‘EB05 demonstrated an 84% reduction in the risk of dying when compared to placebo’

By Benzinga Newsdesk

September 30, 8:02 AM

Mortality reduction in critically ill subjects at 28 days revised favorably, statistically significant EB05 demonstrated an 84% reduction in the risk of dying when compared to placebo Clinical Study Report

EDSA